View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jul. 31, 2017	Aug. 31, 2017
Document And Entity Information
Entity Registrant Name	Advaxis, Inc.
Entity Central Index Key	0001100397
Document Type	10-Q
Document Period End Date	Jul. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--10-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		41,065,835
Trading Symbol	ADXS
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

Condensed Balance Sheets - USD ($)	Jul. 31, 2017	Oct. 31, 2016
Current Assets:
Cash and Cash Equivalents	$ 15,013,455	$ 112,750,980
Investments – Held-to-Maturity	74,391,856	39,336,548
Interest Receivable	226,798	80,142
Prepaid Expenses	1,283,010	812,830
Income Tax Receivable		2,549,862
Deferred Expenses	5,368,234	4,291,385
Other Receivable	1,500,000
Other Current Assets	99,903	53,451
Total Current Assets	97,883,256	159,875,198
Property and Equipment (net of accumulated depreciation)	7,337,337	4,389,074
Intangible Assets (net of accumulated amortization)	4,942,161	4,329,121
Deferred Expenses- net of current portion	59,487
Other Assets	499,427	450,667
TOTAL ASSETS	110,721,668	169,044,060
Current Liabilities:
Accounts Payable	2,981,478	1,720,428
Accrued Expenses	6,162,454	10,905,003
Deferred Revenue	12,106,973	15,020,576
Lease Incentive Obligation	40,226	40,226
Common Stock Warrant Liability		20,156
Total Current Liabilities	21,291,131	27,706,389
Deferred Rent	646,025	475,749
Deferred Revenue- net of current portion	14,130,329	21,234,568
Lease Incentive Obligation – net of current portion	294,991	325,160
Total Liabilities	36,362,476	49,741,866
Commitments and Contingencies
Shareholders' Equity:
Preferred Stock, $0.001 par value; 5,000,000 shares authorized; Series B Preferred Stock; 0 shares issued and outstanding at July 31, 2017 and October 31, 2016. Liquidation preference of $0 at July 31, 2017 and October 31, 2016.
Common Stock - $0.001 par value; 65,000,000 shares authorized, 40,996,342 shares issued and outstanding at July 31, 2017 and 40,057,067 shares issued and 40,041,047 shares outstanding at October 31, 2016.	40,996	40,057
Additional Paid-In Capital	352,199,274	327,098,749
Treasury Stock, at cost, 0 shares at July 31, 2017 and 16,020 shares at October 31, 2016.		(129,787)
Accumulated Deficit	(277,881,078)	(207,706,825)
Total Shareholders' Equity	74,359,192	119,302,194
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 110,721,668	$ 169,044,060

Condensed Balance Sheets (Parenthetical) - USD ($)	Jul. 31, 2017	Oct. 31, 2016
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Series B preferred stock, shares issued	0	0
Series B preferred stock, shares outstanding	0	0
Preferred stock, liquidation preference value	$ 0	$ 0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	40,996,342	40,057,067
Common stock, shares outstanding	40,996,342	40,057,067
Treasury stock, shares	0	16,020

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Income Statement [Abstract]
Revenue	$ 3,051,620		$ 10,267,842	$ 250,000
Operating Expenses
Research and Development Expenses	17,798,139	10,142,232	47,755,429	31,965,596
General and Administrative Expenses	18,063,555	6,423,988	33,171,062	20,395,635
Total Operating Expenses	35,861,694	16,566,220	80,926,491	52,361,231
Loss from Operations	(32,810,074)	(16,566,220)	(70,658,649)	(52,111,231)
Other Income (expense):
Interest Income	184,479	73,872	514,363	216,061
Net Changes in Fair Value of Derivative Liabilities		6,340	20,156	56,214
Other Expense			(123)	(201)
Net Loss Before Income Taxes	(32,625,595)	(16,486,008)	(70,124,253)	(51,839,157)
Income Tax Expense			50,000	14,236
Net Loss	$ (32,625,595)	$ (16,486,008)	$ (70,174,253)	$ (51,853,393)
Net Loss Per Share, Basic and Diluted	$ (0.80)	$ (0.48)	$ (1.74)	$ (1.52)
Weighted Average Number of Shares Outstanding, Basic and Diluted	40,609,794	34,375,814	40,315,356	34,061,127

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
OPERATING ACTIVITIES
Net loss	$ (70,174,253)	$ (51,853,393)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	24,694,464	19,369,948
Gain on change in value of warrants and embedded derivative	(20,156)	(56,214)
Loss on disposal of property and equipment	3,187
Impairment of intangible assets	107,626
Employee stock purchase plan	223,119	28,189
Depreciation expense	553,779	163,581
Amortization expense of intangible assets	239,155	183,184
Lease incentive obligation	(30,169)	375,443
Amortization of premium on held-to-maturity investments	150,062	218,733
Deferred rent	170,276	374,724
Change in operating assets and liabilities:
Interest receivable	(146,656)	5,128
Prepaid expenses	(470,180)	(428,788)
Income tax receivable	2,549,862	1,609,349
Other receivable	(1,500,000)
Other current assets	(46,452)	(13,714)
Deferred expenses	(1,136,336)	(3,614,485)
Other assets	(48,760)	(320,109)
Accounts payable and accrued expenses	(3,634,230)	2,817,033
Deferred revenue	(10,017,842)
Net cash used in operating activities	(58,533,504)	(31,141,391)
INVESTING ACTIVITIES
Purchases of held-to-maturity investments	(73,425,703)	(24,248,963)
Proceeds from maturities and redemptions on held-to-maturity investments	38,220,333	20,649,000
Purchase of property and equipment	(3,419,298)	(2,003,804)
Cost of intangible assets	(959,821)	(602,827)
Net cash used in investing activities	(39,584,489)	(6,206,594)
FINANCING ACTIVITIES
Net proceeds of issuance of common stock	705,868
Proceeds from exercise of warrants	1,125	614,368
Taxes paid related to net share settlement of equity awards	(354,262)	(52,752)
Employee tax withholdings paid on equity awards	(1,547,612)	(1,926,763)
Tax shares sold to pay for employee tax withholdings on equity awards	1,575,349	1,893,645
Net cash provided by financing activities	380,468	528,498
Net decrease in cash and cash equivalents	(97,737,525)	(36,819,487)
Cash and cash equivalents at beginning of period	112,750,980	66,561,683
Cash and cash equivalents at end of period	15,013,455	29,742,196
Supplemental Disclosures of Cash Flow Information
Cash paid for taxes	50,000	50,000
Supplemental Schedule of Non-Cash Investing and Financing Activities
Accrued expenses from consultants settled with common stock	75,000	55,000
Conversion of notes payable into common stock		29,549
Property and equipment included in accounts payable and accrued expenses	$ 85,931	$ 34,797

Nature of Operations

9 Months Ended

Jul. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Operations

1. NATURE OF OPERATIONS

Advaxis, Inc. (“Advaxis” or the “Company”) is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (“Lm” or “Lm Technology^TM”) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors.

Advaxis has developed a strong foothold in the development of immunotherapies, including both axalimogene filolisbac and ADXS-DUAL (ADXS-602) for HPV-related cancers. Axalimogene filolisbac is an Lm–based antigen delivery product directed against the Human Papilloma Virus (“HPV”) and designed to target cells expressing the HPV. ADXS-DUAL, the Company’s second immunotherapy targeting HPV-associated cancers, is an Lm-based immunotherapy that secretes a fusion protein containing E7 protein antigens from both major families of HPV.

The Company completed a randomized Phase 2 study in 110 patients with recurrent metastatic cervical cancer that was shown to have a manageable safety profile, apparent improved survival and objective tumor responses. In addition, the Gynecologic Oncology Group (“GOG”) Foundation, Inc., now part of NRG Oncology, conducted a cooperative group / Company sponsored Phase 2 open-label clinical study of axalimogene filolisbac in patients with persistent or recurrent metastatic cervical cancer with documented disease progression. The study, known as GOG-0265, has successfully completed the first and second stages in its Simon 2-stage design. Upon early closure of this study, the results from both stages totaling 50 patients dosed resulted in a 12-month survival rate of 38.0% with a manageable safety profile. The Company has initiated a registrational Phase 3 clinical trial for the adjuvant treatment of women with high-risk locally advanced cervical cancer and, pending FDA feedback, is planning to initiate a global, randomized, registrational quality clinical trial in 1H 2018 in the metastatic cervical cancer setting with ADXS-DUAL in combination with Bristol-Myers Squibb’s (“BMS”) PD-1 immune checkpoint inhibitor, OPDIVO^® (nivolumab). The Company also plans to pursue registrational opportunities in Europe in 2017 for the metastatic cervical cancer setting as a monotherapy with axalimogene filolisbac.

Axalimogene filolisbac has received United States Food and Drug Administration (“FDA”) orphan drug designation for three HPV-associated cancers: cervical, head and neck, and anal cancer, and has received European Medicines Agency (“EMA”) orphan drug designation for anal cancer. Axalimogene filolisbac has been designated by the FDA as a Fast Track product for adjuvant therapy for high-risk locally advanced cervical cancer patients. It has also been classified as an advanced-therapy medicinal product (“ATMP”) for the treatment of cervical cancer by the European Medicines Agency’s Committee for Advanced Therapies (“CAT”). Axalimogene filolisbac is subject to an agreement with the FDA, under the Special Protocol Assessment (“SPA”) process, for the Phase 3 AIM2CERV trial in patients with high-risk, locally advanced cervical cancer. It is also being evaluated in Company-sponsored trials executed under an Investigational New Drug (“IND”) which include the following: (i) a Phase 1/2 clinical trial alone and in combination with MedImmune, LLC’s (“MedImmune”) investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736), in patients with previously treated metastatic cervical cancer or patients with HPV-associated head and neck cancer; and (ii) a single arm Phase 2 monotherapy study in patients with metastatic anal cancer. In addition to the Company-sponsored trials, axalimogene filolisbac is also being evaluated in two investigator-initiated clinical trials as follows: neoadjuvant treatment of HPV-positive head and neck cancer (Mount Sinai & Baylor College of Medicine), and locally advanced high risk anal cancer (Brown University).

ADXS-PSA (ADXS31-142) is the Company’s Lm–based product candidate designed to target the Prostate Specific Antigen (“PSA”) associated with prostate cancer which is being evaluated in a Phase 1/2 clinical trial alone and in combination with KEYTRUDA^®(pembrolizumab), Merck & Co.’s (“Merck”) humanized monoclonal antibody against PD-1, in patients with previously treated metastatic castration-resistant prostate cancer.

ADXS-HER2 (ADXS31-164) is the Company’s Lm-based product candidate designed for the treatment of Human Epidermal Growth Factor Receptor 2 (“HER2”) expressing cancers, including human and canine osteosarcoma. ADXS-HER2 was evaluated in a Phase 1b clinical trial in patients with metastatic HER2 expressing solid tumors. The Company has evaluated the data, and based on the Company’s priorities, has determined not to pursue further clinical study of ADXS-HER2 at this time but remains open to investigator-initiated research or licensing proposals. Clinical research with ADXS-HER2 in canine osteosarcoma is being developed by the Company’s pet therapeutic partner, Aratana Therapeutics Inc. (“Aratana”), who holds exclusive rights to develop and commercialize ADXS-HER2 and three other Lm -LLO immunotherapies for pet health applications. Aratana has announced that a product license application for use of ADXS-HER2 in the treatment of canine osteosarcoma has been filed with the United States Department of Agriculture (“USDA”). Aratana received communication from the USDA in March 2015 stating that the previously submitted efficacy data for product licensure for AT-014 (ADXS-HER2), the cancer immunotherapy for canine osteosarcoma, was accepted and that it provides a reasonable expectation of efficacy that supports conditional licensure. While additional steps need to be completed, including in the areas of manufacturing and safety, Aratana anticipates that AT-014 could receive conditional licensure from the USDA in 2017.

ADXS-NEO is the Company’s individual Lm-based antigen delivery product combined with a fusion protein based on information captured by comparing a patient’s own DNA with the DNA from that patient’s tumor. The FDA has cleared the Company’s IND application for clinical investigation of a new precision immunotherapy for the treatment of cancers. The Company plans to initiate a Phase 1 study in first half of 2018.

The Company has focused its development efforts on establishing a drug development pipeline that incorporates this technology into therapeutic cancer immunotherapies, with clinical trials currently targeting HPV-associated cancers (cervical cancer, head and neck cancer, and anal cancer), prostate cancer, and canine osteosarcoma. Although no immunotherapies have been commercialized to date, the Company continues to invest in research and development to advance the technology and make it available to patients with many different types of cancer. Pipeline development and the further exploration of the technology for advancement entails risk and expense. The Company anticipates that its ongoing operational costs will increase significantly as it continues conducting and expanding its clinical development programs. In addition to its existing single antigen vectors that target one tumor associated antigen, the Company is actively engaged in the development of new constructs that will address multiple targets that are common to tumor types, as well as mutation-associated epitopes that are specific to an individual patient’s tumor. The Company is also leveraging its Lm Technology™ to target common (public or shared) mutations (hotspots) in tumor driver genes, which it refers to as ADXS-HOT. Lastly, the Company completed construction for its pilot plant at the state-of-the-art manufacturing facility in Princeton, NJ, to produce supplies for its neoepitope and other development programs.

Liquidity and Financial Condition

The Company’s products are being developed and have not generated significant revenues. As of July 31 2017, the Company had approximately $89.4 million in cash, cash equivalents and investments on its balance sheet. The Company believes its current cash position is sufficient to fund its business plan into approximately fiscal 2019. The estimate is based on assumptions that may prove to be wrong, and the Company could use available capital resources sooner than currently expected. Because of the numerous risks and uncertainties associated with the development and commercialization of its product candidates, the Company is unable to estimate the amount of increased capital outlays and operating expenses associated with completing the development of its current product candidates.

The Company recognizes it may need to raise additional capital in order to continue to execute its business plan. There is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company or whether the Company will become profitable and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to scale back its business plan.

Summary of Significant Accounting Policies and Basis of Presentation

9 Months Ended

Jul. 31, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Basis of Presentation

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PRESENTATION

Basis of Presentation - Unaudited Interim Financial Information

The accompanying unaudited interim condensed financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information, and in accordance with the rules and regulations of the SEC with respect to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim condensed financial statements furnished reflect all adjustments (consisting of normal recurring accruals) which are, in the opinion of management, necessary to represent a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These unaudited interim condensed financial statements should be read in conjunction with the financial statements of the Company for the year ended October 31, 2016 and notes thereto contained in the Company’s annual report on Form 10-K for the year ended October 31, 2016, as filed with the SEC on January 9, 2017.

The information presented in the accompanying unaudited condensed balance sheet as of October 31, 2016 has been derived from the Company’s October 31, 2016 audited financial statements.

Estimates

The preparation of financial statements in accordance with U.S. GAAP involves the use of estimates and assumptions that affect the recorded amounts of assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ substantially from these estimates. Significant estimates include the fair value and recoverability of the carrying value of intangible assets (patents and licenses), the fair value of stock options, the fair value of embedded conversion features, warrants and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, based on historical experience and on various other assumptions that it believes to be reasonable under the circumstances. Actual results may differ from estimates.

Reclassifications

Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.

Collaboration Agreements

The Company evaluates whether an arrangement is a collaborative arrangement under the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements, at its inception based on the facts and circumstances specific to the arrangement. The Company also reevaluates whether an arrangement qualifies or continues to qualify as a collaborative arrangement whenever there is a change in either the roles of the participants or the participants’ exposure to significant risks and rewards dependent on the ultimate commercial success of the endeavor. For those collaborative arrangements where it is determined that the Company is the principal participant, costs incurred and revenue generated from third parties are recorded on a gross basis in the financial statements.

From time to time, the Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of products and product candidates. These collaborations generally provide for non-refundable, upfront license fees, research and development and commercial performance milestone payments, cost sharing, royalty payments and/or profit sharing. The Company’s collaboration agreements with third parties are performed on a ‘‘best efforts’’ basis with no guarantee of either technological or commercial success.

Revenue Recognition

The Company is expected to derive the majority of its revenue from patent licensing and research and development services associated with patent licensing. In general, these revenue arrangements provide for the payment of contractually determined fees in consideration for the grant of certain intellectual property rights for patented technologies owned or controlled by the Company. The intellectual property rights granted may be perpetual in nature, or upon the final milestones being met, or can be granted for a defined, relatively short period of time, with the licensee possessing the right to renew the agreement at the end of each contractual term for an additional minimum upfront payment. The Company recognizes licensing fees when there is persuasive evidence of a licensing arrangement, fees are fixed or determinable, delivery has occurred and collectability is reasonably assured.

Revenue associated with nonrefundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue on a straight-line basis over the expected period of performance.

Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved and the milestone payments are due and collectible. If not deemed substantive, the Company recognizes such milestones as revenue on a straight-line basis over the remaining expected performance period under the arrangement. All such recognized revenues are included in collaborative licensing and development revenue in the Company’s statements of operations.

Milestones are considered substantive if all of the following conditions are met: (1) the milestone is nonrefundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended, and the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value.

If product development is successful, the Company will recognize revenue from royalties based on licensees’ sales of its products or products using its technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. If royalties cannot be reasonably estimated or collectability of a royalty amount is not reasonably assured, royalties are recognized as revenue when the cash is received.

Deferred revenue represents the portion of payments received for which the earnings process has not been completed. Deferred revenue expected to be recognized within the next 12 months is classified as a current liability.

An allowance for doubtful accounts is established based on the Company’s best estimate of the amount of probable credit losses in the Company’s existing license fee receivables, using historical experience. The Company reviews its allowance for doubtful accounts periodically. Past due accounts are reviewed individually for collectability. Account balances are charged off against the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. To date, this is yet to occur.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of July 31, 2017 and October 31, 2016, the Company had approximately $8.3 million and $106.7 million, respectively, in cash equivalents.

Concentration of Credit Risk

The Company maintains its cash in bank deposit accounts (checking) that at times exceed federally insured limits. Approximately $13.7 million is subject to credit risk at July 31, 2017. However, these cash balances are maintained at creditworthy financial institutions. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk.

Fair Value of Financial Instruments

The carrying amounts of financial instruments, including cash, accounts payable and accrued expenses approximated fair value as of the balance sheet date presented, because of the relatively short maturity dates on these instruments. The carrying amounts of the financing arrangements issued approximate fair value as of the balance sheet date presented, because interest rates on these instruments approximate market interest rates after consideration of stated interest rates, anti-dilution protection and associated warrants.

Net Loss per Share

Basic net income or loss per common share is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share give effect to dilutive options, warrants, convertible debt and other potential Common Stock outstanding during the period. In the case of a net loss the impact of the potential Common Stock resulting from warrants, outstanding stock options and convertible debt are not included in the computation of diluted loss per share, as the effect would be anti-dilutive. In the case of net income, the impact of the potential Common Stock resulting from these instruments that have intrinsic value are included in the diluted earnings per share. The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of July 31,
	2017		2016
Warrants		3,094,173		3,110,575
Stock Options		3,893,558		3,351,794
Restricted Stock Units		1,527,693		762,909
Total		8,515,424		7,225,278

Stock Based Compensation

The Company has an equity plan which allows for the granting of stock options to its employees, directors and consultants for a fixed number of shares with an exercise price equal to the fair value of the shares at date of grant. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally measured based on contractual terms. The fair value amount is then recognized over the requisite service period, usually the vesting period, in both research and development expenses and general and administrative expenses on the statement of operations, depending on the nature of the services provided by the employees or consultants.

The process of estimating the fair value of stock-based compensation awards and recognizing stock-based compensation cost over their requisite service period involves significant assumptions and judgments. The Company estimates the fair value of stock option awards on the date of grant using the Black Scholes Model (“BSM”) for the remaining awards, which requires that the Company makes certain assumptions regarding: (i) the expected volatility in the market price of its Common Stock; (ii) dividend yield; (iii) risk-free interest rates; and (iv) the period of time employees are expected to hold the award prior to exercise (referred to as the expected holding period). As a result, if the Company revises its assumptions and estimates, stock-based compensation expense could change materially for future grants.

The Company accounts for stock-based compensation using fair value recognition and records stock-based compensation as a charge to earnings net of forfeited awards. As such, the Company recognizes stock-based compensation cost only for those stock-based awards that vest over their requisite service period, based on the vesting provisions of the individual grants.

Recent Accounting Pronouncements

In May 2014, as part of its ongoing efforts to assist in the convergence of GAAP and International Financial Reporting Standards, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which is a new standard related to revenue recognition. Under the new standard, recognition of revenue occurs when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts. The standard must be adopted using either a full retrospective approach for all periods presented in the period of adoption or a modified retrospective approach. In July 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers - Deferral of the Effective Date, which defers the implementation of this new standard to be effective for fiscal years beginning after December 15, 2017. Early adoption is permitted effective January 1, 2017. In March 2016, the FASB issued ASU 2016-08, Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations in the new revenue recognition standard pursuant to ASU 2014-09. In April 2016, the FASB issued ASU 2016-10, Identifying Performance Obligations and Licensing, in May 2016, the FASB issued ASU 2016-12, Narrow-Scope Improvements and Practical Expedients, and in December 2016 the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which amend certain aspects of the new revenue recognition standard pursuant to ASU 2014-09. We are currently evaluating which transition approach we will utilize and the impact of adopting this accounting standard on the Company’s financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”). The standard amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of 2019. Early adoption of ASU 2016-02 is permitted. The new leases standard requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company is currently evaluating the impact of adopting ASU 2016-02 on the Company’s financial statements.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.” The standard significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren’t measured at fair value through net income. The standard will replace today’s “incurred loss” approach with an “expected loss” model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods beginning after December 15, 2019, and interim periods therein. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. This ASU is not expected to have a material impact on the Company’s financial statements.

In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The amendments in this Update clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of businesses. The amendments in this Update provide a screen to determine when a set is not a business. If the screen is not met, it (1) requires that to be considered a business, a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) removes the evaluation of whether a market participant could replace the missing elements. This Update is the final version of Proposed ASU 2015-330 Business Combinations (Topic 805) – Clarifying The Definition of a Business, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements.

In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting” to provide clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this Update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. This Update is the final version of Proposed ASU 2016-360—Compensation—Stock Compensation (Topic 718)—Scope of Modification Accounting, which has been deleted. The amendments in this Update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted. This ASU is not expected to have a material impact on the Company’s financial statements.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on the accompanying condensed financial statements.

Investments

9 Months Ended

Jul. 31, 2017

Schedule of Investments [Abstract]

Investments

3. INVESTMENTS

The following table summarizes the Company’s investment securities at amortized cost as of July 31, 2017 and October 31, 2016:

	July 31, 2017
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross Unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	17,185,953	$	-	$	-	$	17,185,953
Domestic Governmental Agency Loans		2,666,361		-		795		2,665,566
U.S Treasury Notes		54,539,542		-		50,347		54,489,195
Total short-term investment securities	$	74,391,856	$	-	$	51,142	$	74,340,714

	October 31, 2016
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	10,737,563	$	-	$	-	$	10,737,563
Domestic Governmental Agency Loans		2,500,000		-		250		2,499,750
U.S Treasury Notes		26,098,985		2,404		7,556		26,093,833
Total short-term investment securities	$	39,336,548	$	2,404	$	7,806	$	39,331,146

All of the Company’s investments mature within the next 12 months.

Property and Equipment

9 Months Ended

Jul. 31, 2017

Property, Plant and Equipment [Abstract]

Property and Equipment

4. PROPERTY AND EQUIPMENT

Property and equipment consists of the following:

	July 31, 2017			October 31, 2016
Leasehold Improvements	$	2,010,952		$	1,835,602
Laboratory Equipment		4,028,027			2,038,704
Furniture and Fixtures		721,577			549,025
Computer Equipment		394,523			240,910
Construction in Progress		1,152,067			151,368
Total Property and Equipment		8,307,146			4,815,609
Accumulated Depreciation		(969,809	)		(426,535	)
Net Property and Equipment	$	7,337,337		$	4,389,074

Depreciation expense for the three and nine months ended July 31, 2017 and 2016 was $216,376, $553,779, $68,457 and $163,581, respectively.

Intangible Assets

9 Months Ended

Jul. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

5. INTANGIBLE ASSETS

Pursuant to our license agreement with the University of Pennsylvania (“Penn”), the Company is billed actual patent expenses as they are passed through from Penn and are billed directly from our patent attorney. The following is a summary of intangible assets as of the end of the following fiscal periods:

	July 31, 2017			October 31, 2016
License	$	776,992		$	776,992
Patents		5,763,542			4,980,610
Software		83,639			19,625
Total Intangibles		6,624,173			5,777,227
Accumulated Amortization		(1,682,012	)		(1,448,106	)
Intangible Assets	$	4,942,161		$	4,329,121

The expirations of the existing patents range from 2017 to 2037 but the expirations can be extended based on market approval if granted and/or based on existing laws and regulations. Capitalized costs associated with patent applications that are abandoned without future value are charged to expense when the determination is made not to pursue the application. Patent applications having a net book value of $17,745 and $107,626 were abandoned and charged to Research and Development Expenses in the statement of operations for the three and nine months ended July 31, 2017. No patent applications were abandoned during the three or nine months ended July 31, 2016. Amortization expense for intangible assets is included in research and development expenses and aggregated $87,000, $239,155, $64,440 and $183,184 for the three and nine months ended July 31, 2017 and 2016, respectively.

At July 31, 2017, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows:

2017 (Remaining)	$	87,001
2018		348,003
2019		345,603
2020		329,959
2021		320,124
Thereafter		3,511,471
Total	$	4,942,161

Accrued Expenses

9 Months Ended

Jul. 31, 2017

Payables and Accruals [Abstract]

Accrued Expenses

6. ACCRUED EXPENSES:

The following table represents the major components of accrued expenses:

	July 31, 2017		October 31, 2016
Salaries and Other Compensation	$	2,834,381	$	2,467,650
Vendors		516,648		2,098,792
Professional Fees		2,811,425		6,338,561
	$	6,162,454	$	10,905,003

Derivative Instruments

9 Months Ended

Jul. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

7. DERIVATIVE INSTRUMENTS

Warrants

A summary of changes in warrants for the nine months ended July 31, 2017 is as follows:

	Number of			Weighted-Average
	Warrants			Exercise Price
Outstanding Warrants at October 31, 2016:		3,110,575		$	5.04
Issued		-		$	-
Exercised		(225	)	$	5.00
Expired		(16,177	)	$	10.63
Outstanding Warrants at July 31, 2017		3,094,173		$	5.01

At July 31, 2017 and October 31, 2016, the Company had 3,092,395 and 3,092,619 outstanding warrants classified as equity (equity warrants) out of it total 3,094,173 and 3,110,575 warrants, respectively. At issuance, equity warrants are recorded at their relative fair values, using the Relative Fair Value Method, in the shareholders’ equity section of the balance sheet. The equity warrants can only be settled through the issuance of shares and are not subject to anti-dilution provisions.

Warrant Liability

At July 31, 2017, the Company had approximately 2,000 of its total approximately 3.09 million outstanding warrants classified as liabilities (liability warrants). At October 31, 2016, the Company had approximately 18,000 of its total approximately 3.11 million outstanding warrants classified as liabilities (liability warrants). The Company utilizes the BSM to calculate the fair value of these warrants at issuance and at each subsequent reporting date. The liability warrants contain a cash settlement provision in the event of a fundamental transaction (as defined in the Common Stock purchase warrant). Any changes in the fair value of the warrant liability (i.e. - the total fair value of all outstanding liability warrants at the balance sheet date) between reporting periods will be reported on the statement of operations.

At July 31, 2017 and October 31, 2016, the fair value of the warrant liability was $0 and $20,156, respectively. For the three months ended July 31, 2017 and 2016, the Company reported a gain of $0 and $6,340, respectively, due to changes in the fair value of the warrant liability. For the nine months ended July 31, 2017 and 2016, the Company reported a gain of $20,156 and $56,214, respectively, due to changes in the fair value of the warrant liability. In determining the fair value of the warrant liability at July 31, 2017 and October 31, 2016, the Company used the following inputs in its BSM:

	July 31, 2017			October 31, 2016
Exercise Price	$	18.75		$	10.63-18.75
Stock Price	$	6.47		$	8.09
Expected term		0.01 years			0.55-0.75 years
Expected Volatility		67.34	%		81.84%-87.09	%
Risk Free Interest Rate		1.00	%		0.51%-0.66	%

Share Based Compensation

9 Months Ended

Jul. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share Based Compensation

8. SHARE BASED COMPENSATION

Restricted Stock Units (RSUs)

A summary of the Company’s RSU activity and related information for the nine months ended July 31, 2017 is as follows:

	Number of			Weighted-Average
	RSUs			Grant Date Fair Value
Balance at October 31, 2016:		719,448		$	10.77
Granted		1,579,934		$	7.95
Vested		(722,089	)	$	9.03
Cancelled		(49,600	)	$	8.89
Balance at July 31, 2017		1,527,693		$	8.73

As of July 31, 2017, there was approximately $11,266,000 of unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a remaining weighted average vesting period of approximately 2.18 years.

As of July 31, 2017, the aggregate intrinsic value of non-vested RSUs was approximately $9,884,000.

Employee Stock Awards

Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 463,985 shares (452,084 shares on a net basis after employee taxes) and 152,056 shares (149,833 shares on a net basis after employee taxes) for the three months ended July 31, 2017 and 2016, respectively. Total stock compensation expense associated with these awards for the three months ended July 31, 2017 and 2016 was $4,259,656 and $1,220,832 respectively.

Common Stock issued to executives and employees related to vested incentive retention awards, employment inducements, management purchases and employee excellence awards totaled 717,505 shares (674,543 shares on a net basis after employee taxes) and 539,512 shares (532,933 shares on a net basis after employee taxes) during the nine months ended July 31, 2017 and 2016, respectively. Total stock compensation expense associated with these awards for the nine months ended July 31, 2017 and 2016 was $7,328,591 and $4,075,393, respectively.

Furthermore, employees were entitled to receive a performance-based year-end cash bonus. Several employees voluntarily requested to be paid all or a portion of their cash bonus in the Company’s Common Stock instead of cash. During the nine months ended July 31, 2016, the total fair value of these equity purchases were $102,022, or 9,150 shares of the Company’s Common Stock.

Director Stock Awards

Common stock issued to Directors for compensation related to board and committee membership totaled 0 shares and 31,767 shares for the three months ended July 31, 2017 and 2016, respectively. Total Director stock compensation expense for the three months ended July 31, 2017 and 2016 was $101,628 and $311,205, respectively.

Common stock issued to Directors for compensation related to board and committee membership totaled 30,000 and 125,501 shares for the nine months ended July 31, 2017 and 2016, respectively. Total Director stock compensation expense for the nine months ended July 31, 2017 and 2016 was $301,572 and $933,615, respectively.

Stock Options

A summary of changes in the stock option plan for the nine months ended July 31, 2017 is as follows:

	Number of			Weighted-Average
	Options			Exercise Price
Outstanding at October 31, 2016:		3,351,795		$	13.31
Granted		556,952		$	7.71
Exercised		-		$	-
Cancelled		(4,000	)	$	3.42
Expired		(11,189	)	$	17.88
Outstanding at July 31, 2017		3,893,558		$	12.51
Vested and Exercisable at July 31, 2017		2,795,826		$	13.05

Total compensation cost related to the Company’s outstanding stock options, recognized in the statement of operations for the three months ended July 31, 2017 and 2016, was approximately $9,698,000 and $3,108,000, respectively. For the nine months ended July 31, 2017 and 2016, compensation cost related to the Company’s outstanding stock options was approximately $15,889,000 and $13,060,000, respectively.

During the nine months ended July 31, 2017, 556,952 options were granted with a total grant date fair value of approximately $3,542,000. During the nine months ended July 31, 2016, 1,385,000 options were granted with a total grant date fair value of approximately $14,838,000.

As of July 31, 2017, there was approximately $6,342,000 of unrecognized compensation cost related to non-vested stock option awards, which is expected to be recognized over a remaining weighted average vesting period of approximately 1.29 years.

As of July 31, 2017, the aggregate intrinsic value of vested and exercisable options was approximately $27,000.

In determining the fair value of the stock options granted during the nine months ended July 31, 2017 and 2016, the Company used the following inputs in its BSM:

	Nine Months Ended
	July 31, 2017			July 31, 2016
Expected Term		5.50-6.50 years			5.51-6.51 years
Expected Volatility		107.07%-110.93	%		109.23%-115.25	%
Expected Dividends		0	%		0	%
Risk Free Interest Rate		1.26%-1.58	%		1.65%-2.00	%

Shares Issued to Consultants

During the three months ended July 31, 2017, 48,737 shares of Common Stock valued at $416,000 were issued to consultants for services, of which $247,100 represented shares issued for amounts previously accrued. The Company recorded a liability on its balance sheet for $141,800 for shares earned pursuant to consulting agreements but not delivered. During the three months ended July 31, 2016, 31,030 shares of Common Stock valued at $252,000 were issued to consultants for services. The common stock share values were based on the dates the shares vested.

During the nine months ended July 31, 2017, 125,549 shares of Common Stock valued at $1,108,950 were issued to consultants for services, of which $75,000 represented shares issued for amounts previously accrued. The Company recorded a liability on its balance sheet for $141,800 for shares earned pursuant to consulting agreements but not delivered. During the nine months ended July 31, 2016, 120,047 shares of Common Stock valued at $1,097,088 were issued to consultants for services. The common stock share values were based on the dates the shares vested.

The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for the three and nine months ended July 31, 2017 and 2016, respectively:

	Three Months Ended July 31,				Nine Months Ended July 31,
	2017		2016		2017		2016
Research and development	$	1,517,585	$	1,014,034	$	4,271,073	$	7,088,377
General and administrative		12,852,729		3,994,331		20,423,391		12,281,571
Total	$	14,370,314	$	5,008,365	$	24,694,464	$	19,369,948

Collaboration and Licensing Agreements

9 Months Ended

Jul. 31, 2017

Business Combinations [Abstract]

Collaboration and Licensing Agreements

9. COLLABORATION AND LICENSING AGREEMENTS

Amgen

On August 1, 2016, the Company entered into a global agreement (the “Amgen Agreement”) with Amgen for the development and commercialization of the Company’s ADXS-NEO, a novel, preclinical investigational immunotherapy, using the Company’s proprietary Listeria monocytogenes attenuated bacterial vector which activates a patient’s immune system to respond against unique mutations, or neoepitopes, contained in and identified from an individual patient’s tumor. Under the terms of the Amgen Agreement, Amgen receives an exclusive worldwide license to develop and commercialize ADXS-NEO. Advaxis and Amgen will collaborate through a joint steering committee for the development and commercialization of ADXS-NEO. Under the Amgen Agreement, Amgen will fund the clinical development and commercialization of ADXS-NEO and Advaxis will retain manufacturing responsibilities. The Company considered the provisions of the research and development and collaboration guidance in determining how to recognize the clinical development payments to be received from Amgen. The Company determined the clinical development payments should be accounted for within the scope of collaboration arrangement accounting guidance. As a result, the Company will account for the clinical development payments as a reduction of Research and Development Expenses in the statement of operations. During the nine months ended July 31, 2017, the Company received clinical development payments from Amgen totaling $4,500,000. In addition, the Company recorded an expected clinical development payment of $1,500,000 as Other Receivables on the balance sheet. In August 2017, the Company received the $1,500,000 expected clinical development payment from Amgen.

Especificos Stendhal SA de CV

On February 3, 2016, the Company entered into a Co-Development and Commercialization Agreement (the “Stendhal Agreement”) with Especificos Stendhal SA de CV (“Stendhal”), for Advaxis’ lead Lm Technology™ immunotherapy, Axalimogene filolisbac , in HPV-associated cancers. Under the terms of the Stendhal Agreement, Stendhal will pay $10 million (“Support Payments”) towards the expense of AIM2CERV over the duration of the trial. Certain internal expenses of Stendhal up to $1 million shall be counted towards the $10 million in Support Payments. The Support Payments are contingent upon Advaxis achieving annual project milestones. The Company considered the provisions of the research and development and collaboration guidance in determining how to recognize the Support Payments to be received from Stendhal. The Company determined the Stendhal Agreement should be accounted for within the scope of collaboration arrangement accounting guidance. Furthermore, the Company determined that Advaxis is the principal in the Stendhal Agreement. As a result, the Company will account for the Support Payments as a reduction of Research and Development Expenses in the statement of operations. During the nine months ended July 31, 2017, the Company reached the annual project milestones and received a $3,000,000 Support Payment from Stendhal.

Sellas Life Science Group

On February 27, 2017, the Company entered into a license agreement with Sellas Life Science Group (“Sellas”) to develop a novel cancer immunotherapy agent using Advaxis’ proprietary Lm-based antigen delivery product with SELLAS’ patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S)). Pursuant to the agreement, Advaxis will conduct all pre-clinical activities required for an IND filing and Sellas will be responsible for all clinical development and commercial activities. Advaxis will receive future payments of up to $358 million from SELLAS if certain development, regulatory, and commercial milestones are met. SELLAS has agreed to pay Advaxis single-digit to low double-digit royalties based on worldwide net sales upon commercialization. If SELLAS sublicenses its rights, Advaxis will receive a percentage of applicable sublicense revenue paid.

Commitments and Contingencies

9 Months Ended

Jul. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. COMMITMENTS AND CONTINGENCIES

Legal Proceedings

Knoll

On August 21, 2015, Knoll Capital Management L.P. filed a complaint against the Company in the Delaware Court of Chancery. In lieu of continuing to unnecessarily incur litigation expenses, on April 27, 2017, the Company settled the matter for a non-material amount, predominately reimbursed by the Company’s insurance, and the parties entered into a definitive confidential settlement agreement. The Company expressly denies any admission or wrongdoing and the settlement was entered into solely for the purpose of avoiding the burden, inconvenience, and expense of further litigation. On May 11, 2017, following resolution of the matter by the parties, the Court granted a Stipulation Of Dismissal With Prejudice.

Bono

On August 20, 2015, a derivative complaint was filed by a purported Company shareholder in the United States District Court for the District of New Jersey styled David Bono v. O’Connor, et al., Case No. 3:15-CV-006326-FLW-DEA (D.N.J. Aug. 20, 2015) (the “Bono Action”). The complaint is based on general allegations related to certain stock options granted to the individual defendants and generally alleges counts for breaches of fiduciary duty and unjust enrichment. The complaint also alleges additional claims for violation of Section 14(a) of the Securities Exchange Act of 1934 and for waste of corporate assets. The complaint seeks damages and costs of an unspecified amount, disgorgement of compensation obtained by the individual defendants, and injunctive relief.

Defendants filed a motion to dismiss the Bono Action. On May 23, 2016, the United States District Court for the District of New Jersey issued an opinion and order granting in part and denying in part defendants’ motion to dismiss. Specifically, the court denied the motion to dismiss as to the breach of fiduciary duty claim and unjust enrichment claim against the three members of the Compensation Committee, but dismissed without prejudice the breach of fiduciary duty and unjust enrichment claims against the other eight individual defendants [O’Connor, Khleif, McKearn, Patton, Bonstein, Mauro, Mayes, and Petit]. The court dismissed without prejudice the Section 14(a) disclosure claim and waste claims against all defendants. On October 5, 2016, the court denied plaintiff’s motion for reconsideration of its May 23 order. On April 13, 2017, the parties advised the Court that they had reached a tentative agreement in principle to settle the action, which is still subject to negotiating an award of attorneys’ fees and expenses to Plaintiffs’ counsel and a stipulation of settlement, and, ultimately, Court approval.

General

The Company is from time to time involved in legal proceedings in the ordinary course of its business. The Company does not believe that any of these claims and proceedings against it is likely to have, individually or in the aggregate, a material adverse effect on its financial condition or results of operations.

Operating Leases

The Company’s corporate offices are currently located at 305 College Road East, Princeton, New Jersey 08540.

At July 31, 2017 future minimum lease payments by fiscal year of the Company’s operating leases are as follows:

2017 (Remaining)	$	245,466
2018		1,041,895
2019		1,107,385
2020		1,232,907
2021		1,317,640
Thereafter		5,747,340
Total	$	10,692,633

Summary of Significant Accounting Policies and Basis of Presentation (Policies)

9 Months Ended

Jul. 31, 2017

Accounting Policies [Abstract]

Basis of Presentation - Unaudited Interim Financial Information

Basis of Presentation - Unaudited Interim Financial Information

The information presented in the accompanying unaudited condensed balance sheet as of October 31, 2016 has been derived from the Company’s October 31, 2016 audited financial statements.

Estimates

Estimates

Reclassifications

Reclassifications

Collaboration Agreements

Collaboration Agreements

Revenue Recognition

Revenue Recognition

Cash and Cash Equivalents

Cash and Cash Equivalents

Concentration of Credit Risk

Concentration of Credit Risk

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Net Loss Per Share

Net Loss per Share

	As of July 31,
	2017		2016
Warrants		3,094,173		3,110,575
Stock Options		3,893,558		3,351,794
Restricted Stock Units		1,527,693		762,909
Total		8,515,424		7,225,278

Stock Based Compensation

Stock Based Compensation

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Summary of Significant Accounting Policies and Basis of Presentation (Tables)

9 Months Ended

Jul. 31, 2017

Accounting Policies [Abstract]

Schedule of Common Stock Excluded from Diluted Net Loss Per Share

The table sets forth the number of potential shares of Common Stock that have been excluded from diluted net loss per share.

	As of July 31,
	2017		2016
Warrants		3,094,173		3,110,575
Stock Options		3,893,558		3,351,794
Restricted Stock Units		1,527,693		762,909
Total		8,515,424		7,225,278

Investments (Tables)

9 Months Ended

Jul. 31, 2017

Schedule of Investments [Abstract]

Schedule of Investment Securities at Amortized

The following table summarizes the Company’s investment securities at amortized cost as of July 31, 2017 and October 31, 2016:

	July 31, 2017
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross Unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	17,185,953	$	-	$	-	$	17,185,953
Domestic Governmental Agency Loans		2,666,361		-		795		2,665,566
U.S Treasury Notes		54,539,542		-		50,347		54,489,195
Total short-term investment securities	$	74,391,856	$	-	$	51,142	$	74,340,714

	October 31, 2016
	Amortized cost, as adjusted		Gross unrealized holding gains		Gross unrealized holding losses		Estimated fair value
Short-term investments:
Certificates of Deposit	$	10,737,563	$	-	$	-	$	10,737,563
Domestic Governmental Agency Loans		2,500,000		-		250		2,499,750
U.S Treasury Notes		26,098,985		2,404		7,556		26,093,833
Total short-term investment securities	$	39,336,548	$	2,404	$	7,806	$	39,331,146

Property and Equipment (Tables)

9 Months Ended

Jul. 31, 2017

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment consists of the following:

	July 31, 2017			October 31, 2016
Leasehold Improvements	$	2,010,952		$	1,835,602
Laboratory Equipment		4,028,027			2,038,704
Furniture and Fixtures		721,577			549,025
Computer Equipment		394,523			240,910
Construction in Progress		1,152,067			151,368
Total Property and Equipment		8,307,146			4,815,609
Accumulated Depreciation		(969,809	)		(426,535	)
Net Property and Equipment	$	7,337,337		$	4,389,074

Intangible Assets (Tables)

9 Months Ended

Jul. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Intangible Assets

The following is a summary of intangible assets as of the end of the following fiscal periods:

	July 31, 2017			October 31, 2016
License	$	776,992		$	776,992
Patents		5,763,542			4,980,610
Software		83,639			19,625
Total Intangibles		6,624,173			5,777,227
Accumulated Amortization		(1,682,012	)		(1,448,106	)
Intangible Assets	$	4,942,161		$	4,329,121

Schedule of Amortization Expense

At July 31, 2017, the estimated amortization expense by fiscal year based on the current carrying value of intangible assets is as follows:

2017 (Remaining)	$	87,001
2018		348,003
2019		345,603
2020		329,959
2021		320,124
Thereafter		3,511,471
Total	$	4,942,161

Accrued Expenses (Tables)

9 Months Ended

Jul. 31, 2017

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

The following table represents the major components of accrued expenses:

	July 31, 2017		October 31, 2016
Salaries and Other Compensation	$	2,834,381	$	2,467,650
Vendors		516,648		2,098,792
Professional Fees		2,811,425		6,338,561
	$	6,162,454	$	10,905,003

Derivative Instruments (Tables)

9 Months Ended

Jul. 31, 2017

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Warrants Activity

A summary of changes in warrants for the nine months ended July 31, 2017 is as follows:

	Number of			Weighted-Average
	Warrants			Exercise Price
Outstanding Warrants at October 31, 2016:		3,110,575		$	5.04
Issued		-		$	-
Exercised		(225	)	$	5.00
Expired		(16,177	)	$	10.63
Outstanding Warrants at July 31, 2017		3,094,173		$	5.01

Schedule of Fair Value of Warrant Liability

In determining the fair value of the warrant liability at July 31, 2017 and October 31, 2016, the Company used the following inputs in its BSM:

	July 31, 2017			October 31, 2016
Exercise Price	$	18.75		$	10.63-18.75
Stock Price	$	6.47		$	8.09
Expected term		0.01 years			0.55-0.75 years
Expected Volatility		67.34	%		81.84%-87.09	%
Risk Free Interest Rate		1.00	%		0.51%-0.66	%

Share Based Compensation (Tables)

9 Months Ended

Jul. 31, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of RSU Activity and Related Information

A summary of the Company’s RSU activity and related information for the nine months ended July 31, 2017 is as follows:

	Number of			Weighted-Average
	RSUs			Grant Date Fair Value
Balance at October 31, 2016:		719,448		$	10.77
Granted		1,579,934		$	7.95
Vested		(722,089	)	$	9.03
Cancelled		(49,600	)	$	8.89
Balance at July 31, 2017		1,527,693		$	8.73

Summary of Changes in Stock Option Plan

A summary of changes in the stock option plan for the nine months ended July 31, 2017 is as follows:

	Number of			Weighted-Average
	Options			Exercise Price
Outstanding at October 31, 2016:		3,351,795		$	13.31
Granted		556,952		$	7.71
Exercised		-		$	-
Cancelled		(4,000	)	$	3.42
Expired		(11,189	)	$	17.88
Outstanding at July 31, 2017		3,893,558		$	12.51
Vested and Exercisable at July 31, 2017		2,795,826		$	13.05

Summary of Fair Value of Stock Options Granted of BSM

In determining the fair value of the stock options granted during the nine months ended July 31, 2017 and 2016, the Company used the following inputs in its BSM:

	Nine Months Ended
	July 31, 2017			July 31, 2016
Expected Term		5.50-6.50 years			5.51-6.51 years
Expected Volatility		107.07%-110.93	%		109.23%-115.25	%
Expected Dividends		0	%		0	%
Risk Free Interest Rate		1.26%-1.58	%		1.65%-2.00	%

Summary of Share-based Compensation Expense

The following table summarizes share-based compensation expense included in the Statement of Operations by expense category for the three and nine months ended July 31, 2017 and 2016, respectively:

	Three Months Ended July 31,				Nine Months Ended July 31,
	2017		2016		2017		2016
Research and development	$	1,517,585	$	1,014,034	$	4,271,073	$	7,088,377
General and administrative		12,852,729		3,994,331		20,423,391		12,281,571
Total	$	14,370,314	$	5,008,365	$	24,694,464	$	19,369,948

Commitments and Contingencies (Tables)

9 Months Ended

Jul. 31, 2017

Commitments and Contingencies Disclosure [Abstract]

Summary of Future Minimum Payments of Operating Leases

At July 31, 2017 future minimum lease payments by fiscal year of the Company’s operating leases are as follows:

2017 (Remaining)	$	245,466
2018		1,041,895
2019		1,107,385
2020		1,232,907
2021		1,317,640
Thereafter		5,747,340
Total	$	10,692,633

Nature of Operations (Details Narrative)	9 Months Ended
Nature of Operations (Details Narrative)	Jul. 31, 2017 USD ($) Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of patients \| Integer	110
Cash, cash equivalents and investments \| $	$ 89,400,000

Summary of Significant Accounting Policies and Basis of Presentation (Details Narrative) - USD ($)	9 Months Ended
	Jul. 31, 2017	Oct. 31, 2016
Accounting Policies [Abstract]
Cash equivalents	$ 8,300,000	$ 106,700,000
Concentration of credit risk	$ 13,700,000

Summary of Significant Accounting Policies and Basis of Presentation - Schedule of Common Stock Excluded from Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Number of common stock excluded from diluted net loss per share	8,515,424	7,225,278
Warrants [Member]
Number of common stock excluded from diluted net loss per share	3,094,173	3,110,575
Stock Options [Member]
Number of common stock excluded from diluted net loss per share	3,893,558	3,351,794
Restricted Stock Units (RSUs) [Member]
Number of common stock excluded from diluted net loss per share	1,527,693	762,909

Investments (Details Narrative)	9 Months Ended
Investments (Details Narrative)	Jul. 31, 2017
Schedule of Investments [Abstract]
Investments maturity description	All of the Company's investments mature within the next 12 months.

Investments - Schedule of Investment Securities at Amortized (Details) - USD ($)	9 Months Ended	12 Months Ended
	Jul. 31, 2017	Oct. 31, 2016
Amortized cost, as adjusted	$ 74,391,856	$ 39,336,548
Gross unrealized holding gains		2,404
Gross unrealized holding losses	51,142	7,806
Estimated fair value	74,340,714	39,331,146
Certificates of Deposit [Member]
Amortized cost, as adjusted	17,185,953	10,737,563
Gross unrealized holding gains
Gross unrealized holding losses
Estimated fair value	17,185,953	10,737,563
Domestic Governmental Agency Loans [Member]
Amortized cost, as adjusted	2,666,361	2,500,000
Gross unrealized holding gains
Gross unrealized holding losses	795	250
Estimated fair value	2,665,566	2,499,750
U.S Treasury Notes [Member]
Amortized cost, as adjusted	54,539,542	26,098,985
Gross unrealized holding gains		2,404
Gross unrealized holding losses	50,347	7,556
Estimated fair value	$ 54,489,195	$ 26,093,833

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 216,376	$ 68,457	$ 553,779	$ 163,581

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Jul. 31, 2017	Oct. 31, 2016
Property, Plant and Equipment [Abstract]
Leasehold Improvements	$ 2,010,952	$ 1,835,602
Laboratory Equipment	4,028,027	2,038,704
Furniture and Fixtures	721,577	549,025
Computer Equipment	394,523	240,910
Construction in Progress	1,152,067	151,368
Total Property and Equipment	8,307,146	4,815,609
Accumulated Depreciation	(969,809)	(426,535)
Net Property and Equipment	$ 7,337,337	$ 4,389,074

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Finite lived patents expirations year			The expirations of the existing patents range from 2017 to 2037
Book value patent applications, net	$ 17,745		$ 107,626
Amortization of intangible assets	$ 87,000	$ 64,440	$ 239,155	$ 183,184

Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Jul. 31, 2017	Oct. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
License	$ 776,992	$ 776,992
Patents	5,763,542	4,980,610
Software	83,639	19,625
Total intangibles	6,624,173	5,777,227
Accumulated Amortization	(1,682,012)	(1,448,106)
Intangible Assets	$ 4,942,161	$ 4,329,121

Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)	Jul. 31, 2017	Oct. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2017 (Remaining)	$ 87,001
2018	348,003
2019	345,603
2020	329,959
2021	320,124
Thereafter	3,511,471
Total	$ 4,942,161	$ 4,329,121

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Jul. 31, 2017	Oct. 31, 2016
Payables and Accruals [Abstract]
Salaries and Other Compensation	$ 2,834,381	$ 2,467,650
Vendors	516,648	2,098,792
Professional Fees	2,811,425	6,338,561
Accrued Expenses	$ 6,162,454	$ 10,905,003

Derivative Instruments (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Derivative Instruments (Details Narrative) - USD ($)	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016	Oct. 31, 2016
Warrants outstanding	3,094,173		3,094,173		3,110,575
Fair value of warrant liability					$ 20,156
Gain (loss) on change in fair value of warrant liability		$ 6,340	$ 20,156	$ 56,214
Equity Warrants [Member]
Common stock purchase warrant	3,092,395		3,092,395		3,092,619
Warrants outstanding	3,094,173		3,094,173		3,110,575
Liability Warrants [Member]
Common stock purchase warrant	2,000		2,000		18,000
Warrants outstanding	3,090,000		3,090,000		3,110,000

Derivative Instruments - Schedule of Warrants Activity (Details)	9 Months Ended
	Jul. 31, 2017 $ / shares shares
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Number of Warrants, Outstanding, Beginning balance \| shares	3,110,575
Number of Warrants, Issued \| shares
Number of Warrants, Exercised \| shares	(225)
Number of Warrants, Expired \| shares	(16,177)
Number of Warrants, Outstanding, Ending balance \| shares	3,094,173
Weighted-Average Exercise Price, Outstanding, Beginning \| $ / shares	$ 5.04
Weighted-Average Exercise Price, Issued \| $ / shares
Weighted-Average Exercise Price, Exercised \| $ / shares	5.00
Weighted-Average Exercise Price, Expired \| $ / shares	10.63
Weighted-Average Exercise Price, Outstanding, Ending \| $ / shares	$ 5.01

Derivative Instruments - Schedule of Fair Value of Warrant Liability (Details) - $ / shares	9 Months Ended	12 Months Ended
	Jul. 31, 2017	Oct. 31, 2016
Exercise Price	$ 18.75
Stock Price	$ 6.47	$ 8.09
Expected term	4 days
Expected Volatility	67.34%
Risk Free Interest Rate	1.00%
Minimum [Member]
Exercise Price		$ 10.63
Expected term		6 months 18 days
Expected Volatility		81.84%
Risk Free Interest Rate		0.51%
Maximum [Member]
Exercise Price		$ 18.75
Expected term		9 months
Expected Volatility		87.09%
Risk Free Interest Rate		0.66%

Share Based Compensation (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Share Based Compensation (Details Narrative) - USD ($)	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Unrecognized compensation cost related to non-vested stock option awards	$ 6,342,000		$ 6,342,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			1 year 3 months 15 days
Options outstanding, intrinsic value	27,000		$ 27,000
Fair value of equity purchases				$ 102,022
Fair value of equity purchases, shares				9,150
Compensation cost related to outstanding stock options	9,698,000	$ 3,108,000	$ 15,889,000	$ 13,060,000
Number of options, granted			556,952	1,385,000
Fair value of option granted			$ 3,542,000	$ 14,838,000
Restricted Stock Units (RSUs) [Member]
Unrecognized compensation cost related to non-vested stock option awards	11,266,000		$ 11,266,000
Unrecognized compensation cost related to non-vested remaining weighted average vesting period			2 years 2 months 5 days
Options outstanding, intrinsic value	$ 9,884,000		$ 9,884,000
Number of options, granted			1,579,934
Employee Stock Awards [Member]
Share-based compensation, common stock, shares	463,985	152,056	717,505	539,512
Share-based compensation, shares on net basis after employee payroll taxes	452,084	149,833	674,543	532,933
Stock compensation expense	$ 4,259,656	$ 1,220,832	$ 7,328,591	$ 4,075,393
Directors [Member]
Share-based compensation, common stock, shares	0	31,767	30,000	125,501
Stock compensation expense	$ 101,628	$ 311,205	$ 301,572	$ 933,615
Consultants [Member]
Unrecognized compensation cost related to non-vested stock option awards	$ 247,100		247,100
Stock issued during period for services	48,737	31,030
Stock issued during period value for services	$ 416,000	$ 252,000
Recorded a liability	141,800		141,800
Consultants [Member]
Unrecognized compensation cost related to non-vested stock option awards	75,000		$ 75,000
Stock issued during period for services			125,549	120,047
Stock issued during period value for services			$ 1,108,950	$ 1,097,088
Recorded a liability	$ 141,800		$ 141,800

Share Based Compensation - Summary of RSU Activity and Related Information (Details) - $ / shares	9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Beginning Balance	3,351,795
Number of RSUs, Granted	556,952	1,385,000
Number of RSUs, Vested
Ending Balance	3,893,558
Weighted-Average Exercise Price, Outstanding, Beginning	$ 13.31
Weighted-Average Exercise Price, Granted	7.71
Weighted-Average Exercise Price, Vested
Weighted-Average Exercise Price, Outstanding, Ending	$ 12.51
Restricted Stock Units (RSUs) [Member]
Beginning Balance	719,448
Number of RSUs, Granted	1,579,934
Number of RSUs, Vested	(722,089)
Number of RSUs, Cancelled	(49,600)
Ending Balance	1,527,693
Weighted-Average Exercise Price, Outstanding, Beginning	$ 10.77
Weighted-Average Exercise Price, Granted	7.95
Weighted-Average Exercise Price, Vested	9.03
Weighted-Average Exercise Price, Cancelled	8.89
Weighted-Average Exercise Price, Outstanding, Ending	$ 8.73

Share Based Compensation - Summary of Changes in Stock Option Plan (Details) - $ / shares	9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Beginning Balance	3,351,795
Number of Options, Granted	556,952	1,385,000
Number of Options, Exercised
Number of Options, Cancelled	(4,000)
Number of Options, Expired	(11,189)
Ending Balance	3,893,558
Number of Options, Vested and Exercisable	2,795,826
Weighted-Average Exercise Price, Outstanding, Beginning	$ 13.31
Weighted-Average Exercise Price, Granted	7.71
Weighted-Average Exercise Price, Exercised
Weighted-Average Exercise Price, Cancelled	3.42
Weighted-Average Exercise Price, Expired	17.88
Weighted-Average Exercise Price, Outstanding, Ending	12.51
Weighted-Average Exercise Price, Vested and Exercisable	$ 13.05

Share Based Compensation - Summary of Fair Value of Stock Options Granted of BSM (Details)	9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Expected Volatility, Minimum	107.07%	109.23%
Expected Volatility, Maximum	110.93%	115.25%
Expected Dividends	0.00%	0.00%
Risk Free Interest Rate, Minimum	1.26%	1.65%
Risk Free Interest Rate, Maximum	1.58%	2.00%
Minimum [Member]
Expected Term	5 years 6 months	5 years 6 months 3 days
Maximum [Member]
Expected Term	6 years 6 months	6 years 6 months 3 days

Share Based Compensation - Summary of Share-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jul. 31, 2017	Jul. 31, 2016	Jul. 31, 2017	Jul. 31, 2016
Share-based compensation expense	$ 14,370,314	$ 5,008,365	$ 24,694,464	$ 19,369,948
Research and Development [Member]
Share-based compensation expense	1,517,585	1,014,034	4,271,073	7,088,377
General and Administrative [Member]
Share-based compensation expense	$ 12,852,729	$ 3,994,331	$ 20,423,391	$ 12,281,571

Collaboration And Licensing Agreements (Details Narrative) - USD ($)		9 Months Ended
	Feb. 03, 2016	Jul. 31, 2017	Feb. 27, 2017	Oct. 31, 2016
Other receivable		$ 1,500,000
Received payments from related parties		3,000,000
Sellas Life Science Group [Member]
Received payments from related parties			$ 358,000,000
Amgen Agreement [Member]
Payment to acquire research and development		4,500,000
Amgen Agreement [Member] \| August 2017 [Member]
Payment to acquire research and development		$ 1,500,000
Stendhal Agreement [Member]
Support payment expenses	$ 10,000,000
Support payment expense description	Certain internal expenses of Stendhal up to $1 million shall be counted towards the $10 million in Support Payments.
Maximum internal expense	$ 1,000,000

Commitments and Contingencies - Summary of Future Minimum Payments of Operating Leases (Details)	Jul. 31, 2017 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2017 (Remaining)	$ 245,466
2018	1,041,895
2019	1,107,385
2020	1,232,907
2021	1,317,640
Thereafter	5,747,340
Total	$ 10,692,633